Azitra, Inc. (AZTR) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Branford, CT, United States. The current CEO is Francisco D. Salva.
AZTR has IPO date of 2023-06-20, 12 full-time employees, listed on the NYSE, a market capitalization of $2.36M.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
